Advertisement

Journal of Gastroenterology

, Volume 47, Issue 8, pp 912–917 | Cite as

Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial

  • Taiga OtsukaEmail author
  • Seiji Kawazoe
  • Shunya Nakashita
  • Saori Kamachi
  • Satoshi Oeda
  • Chinatsu Sumida
  • Takumi Akiyama
  • Keisuke Ario
  • Masaru Fujimoto
  • Masanobu Tabuchi
  • Takahiro Noda
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac or indomethacin) have shown promising prophylactic activity in post-ERCP pancreatitis (PEP). However, the 100-mg dose is higher than that ordinarily used in Japan.

Methods

We performed a prospective randomized controlled study to evaluate the efficacy of low-dose rectal diclofenac for the prevention of PEP. Patients who were scheduled to undergo ERCP were randomized to receive a saline infusion either with 50 mg of rectal diclofenac (diclofenac group) or without (control group) 30 min before ERCP. The dose of diclofenac was reduced to 25 mg in patients weighing <50 kg. The primary outcome measure was the occurrence of PEP.

Results

Enrollment was terminated early because the planned interim analysis found a statistically significant intergroup difference in the occurrence of PEP. A total of 104 patients were eligible for this study; 51 patients received rectal diclofenac. Twelve patients (11.5%) developed PEP: 3.9% (2/51) in the diclofenac group and 18.9% (10/53) in the control group (p = 0.017). After ERCP, the incidence of hyperamylasemia was not significantly different between the two groups. Post-ERCP pain was significantly more frequent in the control group than in the diclofenac group (37.7 vs. 7.8%, respectively; p < 0.001). There were no adverse events related to diclofenac.

Conclusions

Low-dose rectal diclofenac can prevent PEP.

Keywords

ERCP NSAIDs Complication Prevention Meta-analysis 

Abbreviations

ERCP

Endoscopic retrograde cholangiopancreatography

NSAIDs

Nonsteroidal anti-inflammatory drugs

PEP

Post-ERCP pancreatitis

Notes

Acknowledgments

The authors would like to thank Professor Kazuma Fujimoto (Department of Internal Medicine, Saga Medical School) for his excellent advice.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Vaira D, D’Anna L, Ainley C, Dowsett J, Williams S, Baillie J, et al. Endoscopic sphincterotomy in 1000 consecutive patients. Lancet. 1989;2:431–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Murray B, Carter R, Imrie C, Evans S, O’Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124:1786–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102:978–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR, et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008;23:e11–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Montaño Loza A, Rodríguez Lomelí X, García Correa JE, Dávalos Cobián C, Cervantes Guevara G, Medrano Muñoz F, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig. 2007;99:330–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57:1262–7.PubMedCrossRefGoogle Scholar
  11. 11.
    DeMets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy. 2005;25:18–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Fürstenberg A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut. 1997;40:80–5.PubMedGoogle Scholar
  15. 15.
    Karne S, Gorelick FS. Etiopathogenesis of acute pancreatitis. Surg Clin N Am. 1999;79:699–710.PubMedCrossRefGoogle Scholar
  16. 16.
    Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190:117–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Gross V, Leser HG, Heinisch A, Schölmerich J. Inflammatory mediators and cytokines: new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology. 1993;40:522–30.PubMedGoogle Scholar
  18. 18.
    Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol. 2007;22:977–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol. 2005;3:489–98.PubMedCrossRefGoogle Scholar
  22. 22.
    McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.PubMedCrossRefGoogle Scholar
  23. 23.
    Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997;33:184–213.PubMedCrossRefGoogle Scholar
  24. 24.
    Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc. 2002;56:652–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Cheung J, Tsoi KK, Quan WL, Lau JY, Sung JJ. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastrointest Endosc. 2009;70:1211–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Taiga Otsuka
    • 1
    Email author
  • Seiji Kawazoe
    • 1
  • Shunya Nakashita
    • 1
  • Saori Kamachi
    • 1
  • Satoshi Oeda
    • 1
  • Chinatsu Sumida
    • 1
  • Takumi Akiyama
    • 1
  • Keisuke Ario
    • 1
  • Masaru Fujimoto
    • 1
  • Masanobu Tabuchi
    • 2
  • Takahiro Noda
    • 3
  1. 1.Department of Hepato-Biliary-PancreatologySaga Prefectural Hospital KoseikanSagaJapan
  2. 2.Department of SurgeryKaratsu Red Cross Hospital, FutagoKaratsuJapan
  3. 3.Department of GastroenterologyKaratsu Red Cross Hospital, FutagoKaratsuJapan

Personalised recommendations